Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CRN safe nutrient intake

This article was originally published in The Tan Sheet

Executive Summary

Vitamin and Mineral Safety 2nd Edition provides "supportable data" on safe levels of vitamin and mineral intake that is "far preferable" to Recommended Daily Allowances at a time when Codex Alimentarius is debating science-based standards for supplement regulation, the Council for Responsible Nutrition announces July 30. The publication is a quantitative risk assessment meant to "identify the highest chronic supplemental intake of vitamins and minerals that can be confidently asserted to pose no risk for the majority of the normal adult population," according to author John Hathcock, PhD, VP-scientific & international affairs, who also wrote the first edition in 1997 (1"The Tan Sheet" July 28, 1997)...

You may also be interested in...

CRN suggests nutrient "safety approach" based on "no adverse effect level" values.

VITAMIN E "NO OBSERVED ADVERSE EFFECT LEVEL" OF 80 TIMES RDA PROPOSED BY CRN in a July 8 report entitled "Vitamin and Mineral Safety." The Council for Responsible Nutrition asserts in the report its long-held contention that the Recommended Dietary Allowances set forth by the Food & Nutrition Board of the National Academy of Sciences are "not a valid basis for identifying safe upper intakes of vitamins and minerals." The report provides alternative methods for identifying safe upper nutrient intakes based on the use of "No Observed Adverse Effect Level" (NOAEL) and "Lowest Observed Adverse Effect Level" (LOAEL) values for 25 specific nutrients

P&G Begins US Price Increases In Baby And Feminine Care, Could Expand To Health, Beauty

P&G plans up to double-digit price increases in US baby care, feminine care and adult incontinence and will analyze raw material costs and foreign exchange impacts in its other product categories for other pricing changes.

Vertex’s Price Tag For Taking More Control Of CRISPR-Partnered Candidate: At Least $900m

Vertex and partner CRISPR Therapeutics hope CDX001 can offer a single-use curative regimen for sickle cell disease and beta thalassemia patients. A regulatory filing is possible within 18-24 months.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts